Jaime Bosch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8815222/publications.pdf

Version: 2024-02-01

286 papers	37,523 citations	2215 99 h-index	3182 186 g-index
459 all docs	459 docs citations	459 times ranked	15737 citing authors

#	Article	IF	Citations
1	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65, 310-335.	7.3	1,520
2	Liver cirrhosis. Lancet, The, 2014, 383, 1749-1761.	13.7	1,425
3	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. New England Journal of Medicine, 2010, 362, 2370-2379.	27.0	1,075
4	The treatment of portal hypertension: A meta-analytic review. Hepatology, 1995, 22, 332-354.	7.3	1,015
5	Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. New England Journal of Medicine, 2005, 353, 2254-2261.	27.0	952
6	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. Gastroenterology, 2007, 133, 481-488.	1.3	926
7	Management of Varices and Variceal Hemorrhage in Cirrhosis. New England Journal of Medicine, 2010, 362, 823-832.	27.0	890
8	Baveno VII â€“ Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974.	3.7	890
9	Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology, 1996, 111, 1018-1022.	1.3	838
10	Pharmacological Treatment of Portal Hypertension: An Evidence-Based Approach. Seminars in Liver Disease, 1999, 19, 475-505.	3.6	730
11	Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology, 1990, 99, 1401-1407.	1.3	679
12	The clinical use of HVPG measurements in chronic liver disease. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 573-582.	17.8	576
13	Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet, The, 1995, 346, 1056-1059.	13.7	569
14	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. Gastroenterology, 2004, 126, 469-475.	1.3	468
15	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology, 2003, 37, 902-908.	7.3	456
16	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. Gastroenterology, 2013, 144, 102-111.e1.	1.3	437
17	Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology, 1999, 117, 626-631.	1.3	435
18	Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review. Gastroenterology, 2006, 131, 1611-1624.	1.3	435

#	Article	IF	Citations
19	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. Gastroenterology, 1998, 114, 1296-1303.	1.3	431
20	Prevention of variceal rebleeding. Lancet, The, 2003, 361, 952-954.	13.7	398
21	Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology, 2004, 127, 1123-1130.	1.3	386
22	Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18732-18736.	7.1	375
23	Î² blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608.	13.7	375
24	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology, 2009, 136, 1651-1658.	1.3	372
25	Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology, 1981, 80, 518-525.	1.3	342
26	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. Journal of Hepatology, 2009, 50, 923-928.	3.7	340
27	Portal Hypertension and Its Complications. Gastroenterology, 2008, 134, 1715-1728.	1.3	303
28	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. Gastroenterology, 2014, 146, 412-419.e3.	1.3	285
29	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology, 2006, 43, 492-499.	7.3	282
30	Definitions, methodology and therapeutic strategies in portal hypertension. Journal of Hepatology, 1992, 15, 256-261.	3.7	273
31	Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology, 2001, 34, 671-676.	7.3	273
32	Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology, 2009, 49, 1245-1256.	7.3	272
33	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology, 2008, 47, 1604-1614.	7.3	266
34	Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet, The, 1991, 337, 1431-1434.	13.7	264
35	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. Journal of Hepatology, 2013, 58, 45-50.	3.7	259
36	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology, 2004, 126, 749-755.	1.3	258

#	Article	IF	Citations
37	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1140-1153.	1.3	253
38	Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology, 1992, 103, 1909-1915.	1.3	252
39	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The â€œAnticipateâ€•study. Hepatology, 2016, 64, 2173-2184.	7.3	251
40	The management of portal hypertension: Rational basis, available treatments and future options. Journal of Hepatology, 2008, 48, S68-S92.	3.7	248
41	Current management of portal hypertension. Journal of Hepatology, 2003, 38, 54-68.	3.7	245
42	Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage. Hepatology, 1984, 4, 442-446.	7.3	243
43	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology, 2011, 54, 555-561.	7.3	240
44	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology, 2004, 126, 886-894.	1.3	236
45	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	1.3	232
46	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. American Journal of Gastroenterology, 2006, 101, 506-512.	0.4	228
47	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927.	7.3	226
48	Escherichia coli: an old friend with new tidings. FEMS Microbiology Reviews, 2016, 40, 437-463.	8.6	225
49	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology, 2017, 65, 1293-1305.	7.3	225
50	Functional aspects on the pathophysiology of portal hypertension in cirrhosis. Journal of Hepatology, 2012, 57, 458-461.	3.7	219
51	Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis. Hepatology, 1984, 4, 424-429.	7.3	211
52	Effects of All-Oral Anti-Viral Therapy on HVPG and SystemicÂHemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	1.3	210
53	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. Journal of Hepatology, 2007, 46, 1040-1046.	3.7	203
54	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology, 2000, 32, 471-476.	7.3	196

#	Article	IF	Citations
55	Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. Journal of Hepatology, 2005, 43, 98-103.	3.7	196
56	Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. Journal of Hepatology, 2015, 62, S121-S130.	3.7	189
57	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. Journal of Hepatology, 2015, 62, 1068-1075.	3.7	183
58	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. Seminars in Liver Disease, 2006, 26, 348-362.	3.6	182
59	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology, 2010, 52, 2044-2052.	7.3	180
60	The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelialâ€"stellate cell deactivation induced by statins. Journal of Hepatology, 2013, 58, 98-103.	3.7	180
61	Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology, 2016, 63, 1957-1967.	7.3	174
62	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology, 2019, 70, 458-469.	3.7	173
63	Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology, 1990, 11, 230-238.	7.3	172
64	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642.	7.3	170
65	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology, 2007, 46, 1208-1217.	7.3	166
66	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut, 2015, 64, 1434-1443.	12.1	159
67	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha₁-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83.	7.3	158
68	Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Gastroenterology, 1989, 96, 1110-1118.	1.3	153
69	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. Journal of Hepatology, 2021, 75, S49-S66.	3.7	146
70	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	7.3	144
71	Development of hyperdynamic circulation and response to Î²â€blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206.	7.3	143
72	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology, 2004, 40, 1197-1202.	7.3	142

#	Article	IF	Citations
73	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390.	3.7	141
74	Proteomic and phenotypic profiling of the amphibian pathogen Batrachochytrium dendrobatidis shows that genotype is linked to virulence. Molecular Ecology, 2009, 18, 415-429.	3.9	138
75	Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology, 1995, 109, 1257-1265.	1.3	130
76	Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology, 1995, 108, 1487-1495.	1.3	127
77	Vascular Deterioration in Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, S247-S253.	2.2	126
78	Effects of blood volume restitution following a portal hypertensiveâ€"related bleeding in anesthetized cirrhotic rats. Hepatology, 2001, 33, 821-825.	7.3	125
79	Mitigating amphibian chytridiomycoses in nature. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20160207.	4.0	125
80	Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. Hepatology, 1989, 10, 962-968.	7.3	121
81	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	121
82	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine,the, 2019, 7, 594-604.	10.7	119
83	Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology, 2008, 47, 1248-1256.	7.3	118
84	Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium. Hepatology, 2016, 63, 1368-1380.	7.3	118
85	Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2013, 58, 904-910.	3.7	117
86	Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, september 19, 1992. Journal of Hepatology, 1994, 21, 461-467.	3.7	116
87	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. Journal of Hepatology, 2009, 51, 279-287.	3.7	116
88	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. Journal of Hepatology, 2010, 52, 846-853.	3.7	114
89	Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation. Hepatology, 1995, 22, 106-111.	7.3	113
90	Invasive pathogens threaten species recovery programs. Current Biology, 2008, 18, R853-R854.	3.9	113

#	Article	IF	Citations
91	Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut, 2011, 60, 517-524.	12.1	113
92	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Digestive and Liver Disease, 2012, 44, 855-860.	0.9	113
93	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	3.7	112
94	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology, 1994, 19, 1095-1099.	7.3	111
95	Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: Comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. Hepatology, 1986, 6, 667-672.	7.3	110
96	Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. European Journal of Clinical Investigation, 1979, 9, 69-73.	3.4	107
97	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. Journal of Viral Hepatitis, 2017, 24, 823-831.	2.0	107
98	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
99	Impact of anticoagulation on upperâ€gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	7.3	105
100	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	3.7	104
101	Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. Journal of Hepatology, 2007, 47, 220-227.	3.7	100
102	Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting. Hepatology, 1989, 9, 808-814.	7.3	99
103	Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut, 2009, 58, 1144-1150.	12.1	98
104	Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. Journal of Hepatology, 2016, 64, 834-842.	3.7	97
105	Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology, 2018, 155, 1564-1577.	1.3	97
106	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	1.3	97
107	Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology, 2012, 55, 921-930.	7.3	94
108	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology, 1995, 22, 753-758.	7.3	90

#	Article	IF	Citations
109	Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. Journal of Autoimmunity, 2021, 123, 102710.	6.5	89
110	Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology, 1988, 8, 850-854.	7.3	86
111	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology, 2013, 57, 1172-1181.	7.3	84
112	Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. Journal of Hepatology, 2017, 66, 86-94.	3.7	84
113	The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International, 2018, 12, 1-10.	4.2	81
114	Beta-blockers in cirrhosis: Evidence-based indicationsÂandÂlimitations. JHEP Reports, 2020, 2, 100063.	4.9	81
115	Cirrhosis as new indication for statins. Gut, 2020, 69, 953-962.	12.1	81
116	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient metaâ€analysis. Hepatology, 2017, 66, 1219-1231.	7.3	80
117	Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. Hepatology, 1988, 8, 861-865.	7.3	78
118	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology, 2003, 37, 378-384.	7.3	78
119	How to Prevent Varices From Bleeding: Shades of Greyâ€"The Case for Nonselective Î² Blockers. Gastroenterology, 2007, 133, 2029-2036.	1.3	78
120	The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology, 2000, 31, 581-586.	7.3	77
121	CD84 Leukocyte Antigen Is a New Member of the Ig Superfamily. Blood, 1997, 90, 2398-2405.	1.4	76
122	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology, 2010, 51, 2108-2116.	7.3	74
123	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	4.4	74
124	Carvedilol for portal hypertension in patients with cirrhosis. Hepatology, 2010, 51, 2214-2218.	7.3	73
125	PPARÎ± activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. Journal of Hepatology, 2012, 56, 1033-1039.	3.7	73
126	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016, 63, 1640-1650.	7.3	73

#	Article	IF	Citations
127	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. Journal of Hepatology, 2021, 75, 1367-1376.	3.7	73
128	Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology, 1993, 18, 1082-1089.	7.3	71
129	The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology, 2017, 65, 2031-2044.	7.3	71
130	Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1188-1199.	3.7	70
131	Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology, 1998, 28, 677-682.	7.3	69
132	Emricasan (IDNâ€6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology, 2019, 69, 717-728.	7.3	68
133	Systematic review with metaâ€analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 20-30.	3.7	68
134	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. Hepatology, 1994, 20, 1502-1508.	7.3	67
135	Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology, 1998, 27, 351-356.	7.3	64
136	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver International, 2014, 34, 16-25.	3.9	64
137	Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clinical Gastroenterology and Hepatology, 2015, 13, 2109-2117.	4.4	64
138	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of Hepatology, 2022, 77, 1014-1025.	3.7	64
139	Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology, 1991, 13, 917-922.	7.3	63
140	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology, 1993, 17, 800-806.	7.3	63
141	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. Journal of Hepatology, 2008, 48, 61-67.	3.7	61
142	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. Journal of Hepatology, 2019, 71, 942-950.	3.7	61
143	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. Journal of Hepatology, 2013, 58, 1140-1146.	3.7	60
144	KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clinical Microbiology and Infection, 2015, 21, 786.e9-786.e17.	6.0	60

#	Article	IF	Citations
145	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1846-1853.e1.	4.4	60
146	Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. Journal of Hepatology, 2014, 61, 1321-1327.	3.7	58
147	The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology, 2015, 62, 1584-1592.	7.3	57
148	Prevention and treatment of variceal haemorrhage in 2017. Liver International, 2017, 37, 104-115.	3.9	57
149	Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. Hepatology Communications, 2020, 4, 1263-1278.	4.3	57
150	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology, 1994, 20, 30-33.	7.3	55
151	Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Scientific Reports, 2017, 7, 3255.	3.3	53
152	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology, 1994, 20, 336-341.	7.3	52
153	Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology, 2017, 152, 1358-1365.	1.3	51
154	Development of a new protocol for rapid bacterial identification and susceptibility testing directly from urine samples. Clinical Microbiology and Infection, 2016, 22, 561.e1-561.e6.	6.0	49
155	Pathophysiology of portal hypertension. Gastroenterology Clinics of North America, 1992, 21, 1-14.	2.2	49
156	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088.	7.3	48
157	Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut, 2015, 64, 657-666.	12.1	48
158	New cellular and molecular targets for the treatment of portal hypertension. Hepatology International, 2015, 9, 183-191.	4.2	48
159	Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Digestive and Liver Disease, 2017, 49, 1345-1352.	0.9	48
160	Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology, 1994, 19, 55-60.	7.3	45
161	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology, 2019, 69, 1287-1299.	7.3	45
162	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology, 2022, 75, 1235-1246.	7.3	45

#	Article	IF	Citations
163	Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology, 1981, 80, 518-25.	1.3	45
164	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology, 1993, 18, 628-634.	7.3	44
165	Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology, 2014, 60, 633-647.	7.3	44
166	Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. PLoS ONE, 2016, 11, e0155094.	2.5	44
167	Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. Journal of Hepatology, 2014, 61, 252-259.	3.7	43
168	Mitochondriaâ€targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver International, 2017, 37, 1002-1012.	3.9	42
169	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Hepatology, 1993, 17, 213-218.	7.3	41
170	Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. American Journal of Physiology - Renal Physiology, 2015, 309, G301-G309.	3.4	40
171	Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. Hepatology, 1986, 6, 1244-1247.	7.3	38
172	Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications. Biotechnology and Bioengineering, 2018, 115, 2585-2594.	3.3	38
173	Gastric microcirculatory changes of Portal-hypertensive rats can be attenuated by long-term Estrogen-progestagen treatment. Hepatology, 1994, 20, 1261-1270.	7.3	37
174	Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis. Gastroenterology, 2007, 133, 959-966.	1.3	37
175	Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology, 2013, 58, 1424-1435.	7.3	37
176	Pharmacologic Management of Portal Hypertension. Clinics in Liver Disease, 2014, 18, 303-317.	2.1	37
177	Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyteâ€Mediated Paracrine Mechanism. Hepatology Communications, 2019, 3, 987-1000.	4.3	37
178	Pharmacologic prevention of variceal bleeding and rebleeding. Hepatology International, 2018, 12, 68-80.	4.2	36
179	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599.	3.7	36
180	Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology, 1995, 21, 83-88.	7.3	35

#	Article	IF	Citations
181	Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. Scientific Reports, 2016, 6, 22107.	3.3	35
182	Nuclear deformation mediates liver cell mechanosensing in cirrhosis. JHEP Reports, 2020, 2, 100145.	4.9	35
183	Small diameter shunts should lead to safe expansion of the use of TIPS. Journal of Hepatology, 2021, 74, 230-234.	3.7	34
184	Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats. Hepatology, 1990, 12, 476-480.	7.3	33
185	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology, 2020, 72, 1353-1365.	7.3	32
186	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. Shock, 2017, 47, 370-377.	2.1	30
187	Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
188	Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology, 1994, 19, 1257-1261.	7.3	29
189	Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?. Journal of Hepatology, 2022, 76, 458-463.	3.7	29
190	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	3.7	28
191	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. American Journal of Gastroenterology, 2013, 108, 75-82.	0.4	27
192	Development of Analogues: Successes and Failures. Scandinavian Journal of Gastroenterology, 1998, 33, 3-13.	1.5	27
193	Patients Whose First Episode of Bleeding Occurs While Taking a Î²-Blocker Have High Long-term Risks of Rebleeding and Death. Clinical Gastroenterology and Hepatology, 2012, 10, 670-676.	4.4	26
194	Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. Radiology, 2015, 277, 268-276.	7.3	26
195	Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 474-480.	3.0	25
196	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. American Journal of Gastroenterology, 2015, 110, 985-992.	0.4	25
197	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 2021, 74, 3146-3160.	7.3	25
198	Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow. Hepatology, 1992, 15, 616-622.	7.3	24

#	Article	IF	Citations
199	Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner isâ€¦. Hepatology, 2009, 50, 674-677.	7.3	24
200	Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2101-2109.e1.	4.4	24
201	Esophageal varices: Stage-dependent treatment algorithm. Journal of Hepatology, 2016, 64, 746-748.	3.7	23
202	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Scientific Reports, 2017, 7, 10497.	3.3	23
203	Î²-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology, 1989, 10, 269-272.	7.3	22
204	Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut, 2003, 52, 130-133.	12.1	22
205	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. Seminars in Hematology, 2004, 41, 8-12.	3.4	22
206	Prolonging Survival in Patients With Cirrhosis: Old Drugs With New Indications. Gastroenterology, 2010, 139, 1813-1815.e1.	1.3	22
207	Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. Digestive and Liver Disease, 2015, 47, 1052-1058.	0.9	22
208	Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology, 1999, 30, 445-453.	7.3	21
209	Variceal Bleeding: Pharmacological Therapy. Digestive Diseases, 2005, 23, 18-29.	1.9	21
210	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. Hepatology Communications, 2018, 2, 933-944.	4.3	21
211	Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis. Seminars in Liver Disease, 2019, 39, 178-194.	3.6	21
212	Molecular cloning, characterization, and chromosomal localization of the mouse homologue of CD84, a member of the CD2 family of cell surface molecules. Immunogenetics, 1999, 49, 249-255.	2.4	20
213	A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. Clinical Science, 2014, 127, 527-537.	4.3	20
214	Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 2016, 21, 167-181.	2.4	20
215	Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. Liver International, 2020, 40, 2500-2514.	3.9	20
216	Gene structure of the mouse leukocyte cell surface molecule Ly9. Immunogenetics, 2000, 51, 788-793.	2.4	19

#	Article	IF	Citations
217	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. American Journal of Physiology - Renal Physiology, 2013, 305, G496-G502.	3.4	19
218	Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers, 2021, 13, 2688.	3.7	18
219	New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. Cells, 2019, 8, 1062.	4.1	17
220	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver International, 2019, 39, 705-713.	3.9	17
221	Efficacy of somatostatin and vasopressin in the control of acute variceal hemorrhage. Hepatology, 1985, 5, 344-345.	7.3	15
222	Statins and liver disease: from concern to 'wonder' drugs?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 320-321.	17.8	15
223	Metabolomics as a diagnostic tool for idiopathic nonâ€cirrhotic portal hypertension. Liver International, 2016, 36, 1051-1058.	3.9	15
224	Statins in cirrhosisâ€"Ready for prime time. Hepatology, 2017, 66, 697-699.	7.3	15
225	The treatment of major complications of cirrhosis. Alimentary Pharmacology and Therapeutics, 1994, 8, 639-657.	3.7	14
226	Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension. Gut, 2017, 66, 1306-1320.	12.1	14
227	Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 75, 268-277.	3.6	14
228	A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. Nutrients, 2019, 11, 2358.	4.1	13
229	A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension. Hepatology, 2002, 36, 1330-1332.	7.3	12
230	Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. Scientific Reports, 2022, 12, 3027.	3.3	12
231	Prevention of Variceal Rebleeding: Endoscopes, Drugs, and More. Hepatology, 2000, 32, 660-662.	7.3	11
232	Exudative Ascites in the Course of Acute Type B Hepatitis. Hepatology, 2007, 3, 1013-1015.	7.3	11
233	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. Journal of Hepatology, 2014, 61, 270-277.	3.7	11
234	Prognosis of acute variceal bleeding: Is being on betaâ€blockers an aggravating factor? A shortâ€term survival analysis. Hepatology, 2015, 62, 1840-1846.	7.3	11

#	Article	IF	Citations
235	Betaâ€blockers in 2016: Still the safest and most useful drugs for portal hypertension?. Hepatology, 2016, 63, 1771-1773.	7.3	11
236	Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease, 2020, 52, 958-965.	0.9	11
237	Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence. Hepatology, 2013, 57, 1665-1667.	7.3	10
238	Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. Journal of Vascular and Interventional Radiology, 2016, 27, 1138-1139.	0.5	10
239	Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. Clinical Transplantation, 2018, 32, e13412.	1.6	9
240	Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies. Clinical Liver Disease, 2020, 15, S8-S12.	2.1	7
241	Correspondence. Is the Concept of â€œExudativeâ€•Ascites Useful?. Hepatology, 1984, 4, 982-982.	7.3	6
242	Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 18-19.	1.7	6
243	An apology for beta blockers. Journal of Hepatology, 2014, 61, 450-451.	3.7	6
244	Dermatitis by Dermatophilus congolensis. Clinical Microbiology and Infection, 2015, 21, e73-e74.	6.0	6
245	EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portalsystemic shunt?. Gastrointestinal Endoscopy, 2017, 85, 248-249.	1.0	6
246	Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders. Alimentary Pharmacology and Therapeutics, 2020, 52, 927-928.	3.7	5
247	Neutrophil adhesion is impaired in the mesentery but not in the liver sinusoids of portal hypertensive rats. American Journal of Physiology - Renal Physiology, 2001, 280, G1351-G1359.	3.4	4
248	HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials. Current Hepatology Reports, 2019, 18, 164-173.	0.9	4
249	Letter: nonselective betaâ€blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1370-1371.	3.7	4
250	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology, 1993, 18, 628-634.	7.3	4
251	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology, 1994, 20, 336-341.	7.3	4
252	Editorial: increased cardiac output in cirrhosis â€“ nonâ€invasive assessment of regional blood flow by magnetic resonance angiography. Alimentary Pharmacology and Therapeutics, 2016, 43, 1340-1342.	3.7	3

#	Article	IF	Citations
253	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2396-2398.e3.	4.4	3
254	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	4.9	3
255	Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology, 1994, 19, 1257-1261.	7.3	3
256	Editorial: improving inâ€hospital management of decompensated cirrhosis by a â€˜care bundleâ€™ â€“ hope, frustration, and lessons to learn. Alimentary Pharmacology and Therapeutics, 2017, 45, 754-755.	3.7	2
257	Royal Free Hospitalâ€estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. Liver International, 2021, 41, 819-827.	3.9	2
258	Reply to: â€˜Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinomaâ€™. Journal of Hepatology, 2022, 77, 567-568.	3.7	2
259	Reply:. Hepatology, 2002, 36, 260-260.	7.3	1
260	Is it tea time for portal hypertension?. Clinical Science, 2014, 126, 631-632.	4.3	1
261	Editorial: use of betaâ€blockers and of band ligation in preventing first and recurrent variceal bleedingâ€"â€œreal lifeâ€•vs evidenceâ€based decisions. Alimentary Pharmacology and Therapeutics, 2018, 47, 1222-1223.	3.7	1
262	Bacteremia and intramniotic infection due to Burkholderia cenocepacea. Clinical Microbiology and Infection, 2020, 26, 1564-1565.	6.0	1
263	Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology, 1991, 13, 917-922.	7.3	1
264	Treatment of variceal bleeding in patients with cirrhosis of the liver. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 111-119.	0.1	0
265	OP25.08: Cervical length and gestational age at admission as predictors of intra-amniotic inflammation in preterm labor with intact membranes. Ultrasound in Obstetrics and Gynecology, 2009, 34, 145-145.	1.7	0
266	Reply:. Hepatology, 2011, 53, 2141-2142.	7.3	0
267	EASL Recognition Award Recipient 2015. Journal of Hepatology, 2015, 63, 787-788.	3.7	0
268	EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann. Journal of Hepatology, 2016, 64, 996-997.	3.7	0
269	Reply. Hepatology, 2016, 64, 2274-2274.	7.3	0
270	Reply. Gastroenterology, 2016, 151, 1037-1038.	1.3	0

#	Article	IF	Citations
271	Reply. Hepatology, 2017, 65, 2121-2122.	7.3	0
272	Reply. Hepatology, 2017, 65, 386-387.	7.3	0
273	Muscle abnormalities in cirrhosis: Calling for more strength in evaluation and prevention. Digestive and Liver Disease, 2019, 51, 1500-1501.	0.9	0
274	Skin infection by Corynebacterium diphtheriae and Streptococcus pyogenes: an unusual association. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 678-679.	0.5	0
275	Reply. Hepatology, 2019, 70, 1079-1080.	7.3	0
276	Reply to: â€œAchieving an effective pressure reduction after TIPS: The need for a new targetâ€• Journal of Hepatology, 2021, 75, 248-249.	3.7	0
277	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€"Hepatorenal Syndrome. Annals of Internal Medicine, 2021, 174, HO2-HO3.	3.9	0
278	Reply to: â€œFirst things first! Can bacterial infections be considered as decompensating events per se?â€• Journal of Hepatology, 2021, 75, 1242-1243.	3.7	0
279	Treatment of variceal bleeding in patients with cirrhosis of the liver. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 111-119.	0.1	0
280	Hepatopulmonary syndrome and portopulmonary hypertension. , 0, , 751-756.		0
281	Adenocarcinoma (Gastric Cancer and Miscellaneous Malignancy). , 0, , 248-253.		0
282	Functional Gastrointestinal Disease. , 0, , 54-60.		0
283	Reply. Hepatology, 2022, 76, E5-E6.	7.3	0
284	Evaluation of the portal hypertensive patient. Journal of Gastroenterology and Hepatology (Australia), 1989, 4 Suppl 1, 39-47.	2.8	0
285	Diagnosis and evaluation of portal hypertension. Zeitschrift Fur Gastroenterologie, 1988, 26 Suppl 2, 8-14.	0.5	0
286	Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs, 2022, 31, 825-842.	4.1	0